Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation
Investigative Ophthalmology & Visual Science · 2026-09-16 · 67 (11) · 31
DOI: 10.1167/iovs.67.11.31 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2026-09-16. Written by Qian Liu and 10 co-authors. Institution: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Major MEDLINE topics: Carnitine, Diabetes Mellitus, Experimental, Diabetic Angiopathies, Diabetic Retinopathy. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Diabetic retinopathy (DR) is often recognized as a marker of systemic microvascular disease, but the metabolic links to other complications, such as diabetic nephropathy (DN), remain unclear. We aimed to identify systemic metabolic signatures shared by DR and DN and investigate their potential causal mechanisms.
Methods
Multi-tissue metabolomic profiling of the retina, plasma, and kidney was performed in streptozotocin-induced diabetic mice. Clinical relevance was supported by public human DR and DN transcriptomic datasets. Causal relationships were assessed by two-sample Mendelian randomization (MR) using eQTLGen and genome-wide association study (GWAS) summary statistics. Single-cell in silico perturbation analysis was performed to predict organ-specific functional consequences.
Results
Cross-organ metabolomic profiling identified a conserved systemic lipotoxic signature, yielding a predictive plasma panel comprised of free carnitine and two long-chain acylcarnitines. Clinical transcriptomics and MR analyses pinpointed the synchronous downregulation of the SLC22A5 and CPT2 axis as a causal genetic signature of this lipid imbalance. Furthermore, in silico single-cell analyses revealed that this shared metabolic disturbance induced distinct transcriptional responses across tissues, suggesting tissue-specific molecular responses that may contribute to organ-specific microvascular dysfunction.
Conclusions
Both DR and DN are associated with systemic disruption of acylcarnitine metabolism. A circulating carnitine/acylcarnitine signature may serve as a non-invasive indicator of microvascular risk, and the SLC22A5-CPT2 axis represents a potential therapeutic target.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.
- The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.
- Department of Ophthalmology, The Second Affiliated Hospital of Nantong University, Nantong, China.
- Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cite
APA
Liu, Q., Liu, Y., Yang, X., Liu, T., Zhao, Y., Xia, J., Fu, X., Yao, M., Wang, Y., Jiang, Q., & Yan, B. (2026). Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation. Investigative Ophthalmology & Visual Science, 67(11), 31. https://doi.org/10.1167/iovs.67.11.31
Vancouver
Liu Q, Liu Y, Yang X, Liu T, Zhao Y, Xia J, et al. Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation. Investigative Ophthalmology & Visual Science. 2026;67(11):31. doi:10.1167/iovs.67.11.31
BibTeX
@article{Liu2026,
author = {Liu, Qian and Liu, Yan and Yang, Xiongyi and Liu, Tianyi and Zhao, Ya and Xia, Jiao and Fu, Xueyun and Yao, Mudi and Wang, Yufan and Jiang, Qin and Yan, Biao},
title = {Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
volume = {67},
number = {11},
pages = {31},
doi = {10.1167/iovs.67.11.31}
}
EUVIMED